THE FUTURE OF PET MEDICINE

We are offering the following collaboration opportunities:

1. Commercial partnerships in various geographies for the development of LS-001, polymer based LAI for treatment of feline hyperthyroidism, and LS-002, for pain management.
2. License our biodegradable polymer based LAI platform for delivery of a partner’s proprietary product.
3. License our pipeline of early product candidates to address chronic conditions such as :
   • • Analgesia; 
     • Inflammation;
     • Hypertension;
     • Endocrine disorders